Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs

AAPS Journal

Volumn 17, Issue 4, 2015, Pages 853-870

  Borghardt, Jens Markus ^a   Weber, Benjamin ^b   Staab, Alexander ^b   Kloft, Charlotte ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

inhalation; mathematical models; physiologically based pharmacokinetic models; population pharmacokinetics; pulmonary absorption

Indexed keywords

AMIKACIN; BRONCHODILATING AGENT; BUDESONIDE; CICLESONIDE; CIPROFLOXACIN; FENOTEROL; FLUNISOLIDE; FLUTICASONE PROPIONATE; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; INSULIN; INSULIN LISPRO; SALBUTAMOL; TRIAMCINOLONE ACETONIDE; DRUG;

ARTICLE; BINDING AFFINITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUBILITY; HUMAN; LIMIT OF QUANTITATION; LUNG; MACROPHAGE; MATHEMATICAL MODEL; MUCOCILIARY CLEARANCE; PHARMACOLOGICAL SCIENCE; ANIMAL; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG DESIGN; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASES; METABOLISM; PHARMACOKINETICS; THEORETICAL MODEL;

ADMINISTRATION, INHALATION; ANIMALS; COMPUTER SIMULATION; DRUG DESIGN; HUMANS; LUNG DISEASES; MODELS, BIOLOGICAL; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84931569963     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-015-9760-6     Document Type: Article

References (99)

1. Vlasakakis G, Comets E, Keunecke A, Gueorguieva I, Magni P, Terranova N, et al. White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation. CPT: Pharmacometrics Syst Pharmacol. 2013;2:e40.
2. Lee JY, Garnett CE, Gobburu JV, Bhattaram VA, Brar S, Earp JC, et al. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin Pharmacokinet. 2011;50(10):627–35.
3. Manolis E, Rohou S, Hemmings R, Salmonson T, Karlsson M, Milligan PA. The role of modeling and simulation in development and registration of medicinal products: output from the EFPIA/EMA modeling and simulation workshop. CPT: Pharmacometrics Syst Pharmacol. 2013;2:e31.
4. Kandala B, Hochhaus G. Pharmacometrics in pulmonary diseases. In: Schmidt S, Derendorf H, editors. Applied Pharmacometrics. 1st ed. Springer; 2014. p. 349–82.
5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2014.
6. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2014.
7. Rohatagi S, Appajosyula S, Derendorf H, Szefler S, Nave B, Zech K, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol. 2004;44(1):37–47.
8. Jennings BH, Andersson K-E, Johansson SA. Assessment of systemic effects of inhaled glucocorticosteroids: comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol. 1991;40:77–82.
9. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159(9):941–55.
10. Hochhaus G, Möllmann H, Derendorf H, Gonzales-Rothi RJ. Pharmacokinetic/pharmacodynamic aspects of aersosol therapy using glucocorticoids as a model. J Clin Pharmacol. 1997;37(10):881–92.
11. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 2004;27(10):2356–62.
12. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588–99.
13. Olsson B, Bondesson E, Borgström L, Edsbacker S, Eirefelt S, Ekelund K, et al. Pulmonary drug metabolism, clearance, and absorption. In: Smyth HDC, Hickey AJ, editors. Controlled Pulmonary Drug Delivery. 1st ed. Springer; 2011. p. 21-50.
14. Ruge CA, Kirch J, Lehr CM. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. Lancet Respir Med. 2013;1(5):402–13.
15. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67–74.
16. Upton RN, Doolette DJ. Kinetic aspects of drug disposition in the lungs. Clin Exp Pharmacol Physiol. 1999;26(5–6):381–91.
17. International Commission on Radiological Protection. ICRP Publication 66 human respiratory tract model for radiological protection. New York: Elsevier; 1994.
18. Brown Jr RA, Schanker LS. Absorption of aerosolized drugs from the rat lung. Drug Metab Dispos. 1983;11(4):355–60.
19. Schanker LS, Mitchell EW, Brown Jr RA. Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection. Drug Metab Dispos. 1986;14(1):79–88.
20. French MC, Wishart GN. Isolated perfused rabbit lung as a model to study the absorption of organic aerosols. J Pharmacol Methods. 1985;13:241–8.
21. Folkesson HG, Matthay MA, Westrom BR, Kim KJ, Karlsson BW, Hastings RH. Alveolar epithelial clearance of protein. J Appl Physiol. 1996;80(5):1431–45.
22. Kuempel ED, O'Flaherty EJ, Stayner LT, Smith RJ, Green FH, Vallyathan V. A biomathematical model of particle clearance and retention in the lungs of coal miners. Regul Toxicol Pharmacol: RTP. 2001;34(1):69–87.
23. Gregoratto D, Bailey MR, Marsh JW. Modelling particle retention in the alveolar-interstitial region of the human lungs. J Radiol Prot. 2010;30(3):491–512.
24. Edsbäcker S, Wollmer P, Selroos O, Borgstrom L, Olsson B, Ingelf J. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids? Pulm Pharmacol Ther. 2008;21(2):247–58.
25. Isaar M, Cary M, Khan P, Hochhaus G. Pharmacokinetics and pharmacodynamics of drug delievered to the lungs. In: Hickey AJ, editor. Pharmaceutical Inhalation Aerosol Technology. 2nd ed. CRC Press; 2003. p. 215-52.
26. Carvalho TC, Peters JI, Williams 3rd RO. Influence of particle size on regional lung deposition—what evidence is there? Int J Pharm. 2011;406(1–2):1–10.
27. Isaacs KK, Rosati JA, Martonen TB. Mechanisms of particle deposition. In: Ruzer LS, Harley NH, editors. Aerosols Handbook. 2nd ed. New York: CRC Press; 2012. p. 47–74.
28. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhaland delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56:600–12.
29. Perrie Y, Badhan RK, Kirby DJ, Lowry D, Mohammed AR, Ouyang D. The impact of ageing on the barriers to drug delivery. J Control Release: Off J Control Release Soc. 2012;161(2):389–98.
30. Withers RT, Bourdon PC, Crockett A. Lung volume standards for healthy male lifetime nonsmokers. Chest. 1988;93(1):91–7.
31. Pichelin M, Caillibotte G, Katz I, Martonen T. Categorization of lung morphology based on FRC and height: computer simulations of aerosol deposition. Aerosol Sci Technol. 2012;46:70–81.
32. Darquenne C. Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv. 2012;25(3):140–7.
33. Brutsche MH, Brutsche IC, Munavvar M, Langley SJ, Masterson CM, Daley-Yates P, et al. Comparison of pharmacokinetic and systemic effects of inhaled fluticasone proprionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet. 2000;356:556–61.
34. Singh SD, Whale C, Houghton N, Daley-Yates P, Woodcock AA. Pharmacokinetic and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. Br J Clin Pharmacol. 2003;55:375–81.
35. Weiner P, Berar-Yanay N, Davidovich A, Magadle R. Nocturnal cortisol secretion in asthmatic parients after inhalation of fluticasone propionate. Chest. 1999;116(4):931–4.
36. Mortimer KJ, Tattersfield AE, Tang Y, Wu K, Lewis S, Hochhaus G, et al. Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction. Br J Clin Pharmacol. 2007;64(4):439–44.
37. Imai Y, Miki T, Ishikawa T, Aoki T, Yamaguchi T. Deposition of micrometer particles in pulmonary airways during inhalation and breath holding. J Biomech. 2012;45(10):1809–15.
38. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89(2):259–67.
39. Jones HM, Gardner IB, Watson KJ. Modelling and PBPK simulation in drug discovery. AAPS J. 2009;11(1):155–66.
40. Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation. 2nd ed. Springer Science and Business Media; 2011.
41. Landersdorfer CB, Jusko WJ. Pharmacokinetic/pharmacodynamic modeling of glucose clamp effects of inhaled and subcutanous insulin in healthy volunteers and diabetic patients. Drug Metab Pharmacokinet. 2010;25(5):418–29.
42. Sakagami M. Insulin disposition in the lung following oral inhalation in humans: a meta-analysis of its pharmacokinetics. Clin Pharmacokinet. 2004;43(8):539–52.
43. Gloede E, Cichocki JA, Baldino JB, Morris JB. A validated hybrid computational fluid dynamics-physiologically based pharmacokinetic model for respiratory tract vapor absorption in the human and rat and its application to inhalation dosimetry of diacetyl. Toxicol Sci: Off J Soc Toxicol. 2011;123(1):231–46.
44. Morris JB. Biologically-based modeling insights in inhaled vapor absorption and dosimetry. Pharmacol Ther. 2012;136(3):401–13.
45. Gaz C, Cremona G, Panunzi S, Patterson B, De Gaetano A. A geometrical approach to the PKPD modelling of inhaled bronchodilators. J Pharmacokinet Pharmacodyn. 2012;39(5):415–28.
46. Applied Research Associates. Multiple-path dosimetry model 2009 [cited 2014 14 Oct]. Available from: http://www.ara.com/products/mppd.
47. Meltzer EO, Kuna P, Nolte H, Nayak AS, Laforce C. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J. 2012;39(2):279–89.
48. Chaudhuri SR, Lukacova V. Simulating delivery of pulmonary (and intranasal) aerosolised drugs. Orally Inhaled Nasal Drug Prod. 2010:26-30.
49. Collingwood SP, Coe D, Pryde D, Lock R. Respiratory drug discovery, current developments and future challenges: highlights from the Society of Medicines Research Symposium, held on June 14 th, 2012–Horsham, UK. Drugs Future. 2012;37(8):619–25.
50. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001;50 Suppl 1:S41–67.
51. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc. 1897;19:930–4.
52. Chaudhuri SR, Lukacova V, Woltosz WS. Application of a respiratory PBPK model for predicting deposition and disposition following inhaled administration of morphine. AAPS Annual Meeting and Exposition/FIP Pharmaceutical Sciences 2010 World Congress; 14-18 Nov 2010; New Orleans, LA2010.
53. Chaudhuri SR, Lukacova V, Woltosz WS, editors. Simulating the disposition of triamcinolone acetonide following oral and pulmonary administration. Respiratory Drug Delivery Europe 2011; 2011 3-6 May 2011; Berlin, Germany: Davis Healthcare International Publishing, LLC.
54. Miller NA, Chaudhuri SR, Lukacova V, Damian-Iordache V, Bayliss MK, Woltosz WS, editors. Development of a physiologically based pharmacokinetic (PBPK) model for predicting deposition and disposition following inhaled and intranasal administration. Respiratory Drug Delivery 2010; 2010 25-29 Apr 2010; Orlando, Florida: Davis Healthcare International Publishing, LLC.
55. Lukacova V, Chaudhuri SR, Miller NA, Damian-Iordache V, Bolger MB, Woltosz WS, editors. Simulation of tobramycin pharmacokinetics after pulmonary administration. 37th Annual Meeting & Exposition of the Controlled Release Society 2010; 2010 10-14 Jul 2010; Portland, Oregon.
56. Simcyp Limited. Lung absorption [cited 2014 6 Jun]. Available from: http://www.simcyp.com/ResearchDevelopment/SimcypScience/Absorption/Pulmonary+absorption/.
57. Borghardt JM, Weber B, Staab A, Kunz C, Schiewe J, Kloft C. Expanding the mechanistic knowledge about pulmonary absorption processes using a population pharmacokinetic model for inhaled olodaterol. Respiratory Drug Delivery; 2014; Fajardo, Puerto Rico: Davis Healthcare International Publishing, LLC.
58. Parra-Guillen Z, Weber B, Sharma A, Freijer J, Retlich S, Borghardt JM, et al. Population pharmacokinetic analysis of tiotropium in healthy volunteers after intravenous administration and inhalation. J Pharmacokinet Pharmacodyn. 2014;41(1):S54.
59. Bartels C, Looby M, Sechaud R, Kaiser G. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. Br J Clin Pharmacol. 2013;76(6):868–79.
60. Dershwitz M, Walsh JL, Morishige RJ, Connors PM, Rubsamen RM, Shafer SL, et al. Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. Anesthesiology. 2000;93(3):619–28.
61. Rohatagi S, Krishnaswami S, Pfister M, Sahasranaman S. Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model. Am J Ther. 2005;12:385–97.
62. Rohatagi S, Arya V, Zech K, Nave R, Hochhaus G, Jensen BK, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol. 2003;43(4):365–78.
63. Xu J, Nave R, Lahu G, Derom E, Derendorf H. Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. J Clin Pharmacol. 2010;50(10):1118–27.
64. Minto C, Li B, Tattam B, Brown K, Seale JP, Donnelly R. Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation–intersubject variability in systemic absorption from the lung. Br J Clin Pharmacol. 2000;50(2):116–24.
65. Wu K, Goyal N, Stark JG, Hochhaus G. Evaluation of the administration time effect on the cumulative cortisol suppression and cumulative lymphocytes suppression for once-daily inhaled corticosteroids: a population modeling/simulation approach. J Clin Pharmacol. 2008;48(9):1069–80.
66. Krishnaswami S, Hochhaus G, Möllmann H, Barth J, Derendorf H. Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. Int J Clin Pharmacol Ther. 2005;43(3):117–22.
67. Blake K, Mehta R, Spencer T, Kunka RL, Hendeles L. Bioavailability of inhaled fluticasone propionate via chambers/masks in young children. Eur Respir J. 2012;39(1):97–103.
68. Anderson PJ, Zhou X, Breen P, Gann L, GLogsdon TW, Compadre CM, et al. Pharmacokinetics of (R, S)-albuterol after aerosol inhalation in healthy adult volunteers. J Pharm Sci. 1998;87(7):841–4.
69. Maier G, Rubino C, Hsu R, Grasela T, Baumgartner RA. Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma. Pulm Pharmacol Ther. 2007;20(5):534–42.
70. Derks MG, van den Berg BT, van der Zee JS, Braat MC, van Boxtel CJ. Biphasic effect-time courses in man after formoterol inhalation: eosinopenic and hypokalemic effects and inhibition of allergic skin reactions. J Pharmacol Exp Ther. 1997;283(2):824–32.
71. Matsushima S, Matthews I, Woessner R, Pinault G, Hara H, Wilkins J, et al. Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting beta2-agonist, in different ethnic populations. Int J Clin Pharmacol Ther. 2012;50(8):545–56.
72. Diderichsen PM, Cox E, Martin SW, Cleton A, Ribbing J. Characterizing systemic exposure of inhaled drugs: application to the long-acting beta2-agonist PF-00610355. Clin Pharmacokinet. 2013;52(6):443–52.
73. Peng AW, Hussey EK, Moore KH. A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration. J Clin Pharmacol. 2000;40(3):242–9.
74. Yoshihara K, Ishizuka H, Kubo Y. Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection. Drug Metab Pharmacokinet. 2013;28(5):416–26.
75. Marino MT, Costello D, Baughman R, Boss A, Cassidy J, Damico C, et al. Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes. Clin Pharmacol Ther. 2010;88(2):243–50.
76. Ting L, Aksenov S, Bhansali SG, Ramakrishna R, Tang P, Geller DE. Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients. CPT: Pharmacometrics Syst Pharmacol. 2014;3:e99.
77. Shah B, Jensen BK, Zhang J, Hunt T, Rohatagi S. Effect of food on pharmacokinetics of an inhaled drug: a case study with a VLA-4 antagonist, HMR1031. J Clin Pharmacol. 2003;43(12):1341–9.
78. Avram MJ, Spyker DA, Henthorn TK, Cassella JV. The pharmacokinetics and bioavailability of prochlorperazine delivered as a thermally generated aerosol in a single breath to volunteers. Clin Pharmacol Ther. 2009;85(1):71–7.
79. Potocka E, Baughman RA, Derendorf H. Population pharmacokinetic model of human insulin following different routes of administration. J Clin Pharmacol. 2011;51(7):1015–24.
80. Stass H, Nagelschmitz J, Willmann S, Delesen H, Gupta A, Baumann S. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. Clin Drug Investig. 2013;33(6):419–27.
81. Weber B, Hochhaus G. A pharmacokinetic simulation tool for inhaled corticosteroids. AAPS J. 2013;15(1):159–71.
82. Cheng YS. Modeling aerosol drug delivery. In: Gradon L, editor. Optimization of aerosol drug delivery. 1st ed. Netherlands: Springer; 2003. p. 165–88.
83. Longest PW, Hindle M, Choudhuri SD, Xi J. Comparison of ambient and spray aerosol in a standard induction port and more realistic mouth-throat geometry. Aerosol Sci. 2008;39:572–91.
84. DeHaan WH, Finlay WH. Predicting extrathoracic deposition from dry powder inhalers. Aerosol Sci. 2004;35:309–31.
85. Wong W, Fletcher DF, Traini D, Chan HK, Crapper J, Young PM. Particle aerosolisation and break-up in dry powder inhalers 1: evaluation and modelling of venturi effects for agglomerated systems. Pharm Res. 2010;27(7):1367–76.
86. Longest PW, Holbrook LT. In silico models of aerosol delivery to the respiratory tract—development and applications. Adv Drug Deliv Rev. 2012;64(4):296–311.
87. Cuddihy RG, Fisher GL, Kanapilly GM, Moss OR, Phalen RF, Schlesinger RB, et al. Report No. 125—deposition, retention and dosimetry of inhaled radioactive substances. NCRP; 1997.
88. MacIntyre AC, Cutler DJ. The potential role of lysosomes in tissue distribution of weak bases. Biopharm Drug Dispos. 1988;9(6):513–26.
89. Vauquelin G, Charlton SJ. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol. 2010;161(3):488–508.
90. Anderson GP, Linden A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J. 1994;7(3):569–78.
91. Olsson B, Borgstrom L, Lundback H, Svensson M. Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products. J Aerosol Med Pulm Drug Deliv. 2013;26(6):355–69.
92. Neale MG, Brown K, Foulds RA, Lal S, Morris DA, Thomas D. The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease. Br J Clin Pharmacol. 1987;24(4):493–501.
93. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481–504.
94. Hochhaus G, Schmidt E-W, Rominger KL, Möllmann H. Pharmacokinetik/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. Pharm Res. 1992;9(3):291–7.
95. Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim KJ, et al. The particle has landed—characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv. 2010;23 Suppl 2:S71–87.
96. Agu RU, Ugwoke MI. In vitro and in vivo testing methods for respiratory drug delivery. Expert Opin Drug Deliv. 2011;8(1):57–69.
97. Tolman JA, Williams 3rd RO. Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties. Drug Dev Ind Pharm. 2010;36(1):1–30.
98. Okusanya OO, Bhavnani SM, Hammel JP, Forrest A, Bulik CC, Ambrose PG, et al. Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies. Antimicrob Agents Chemother. 2014;58(9):5005–15.
99. Burmeister Getz E, Fisher DM, Fuller R. Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J Clin Pharmacol. 2009;49(9):1025–36.